FDA Approves TRYNGOLZA — Ionis Pharmaceuticals, Inc.

On December 19, 2024, Ionis Pharmaceuticals received FDA approval for TRYNGOLZA (olezarsen sodium), a novel subcutaneous product addressing an unmet need in systemic fat disorder management. This clearance represents a significant expansion for the company, marked by a novel administration route and offering a new treatment option in a market currently defined by limited modalities.